Fresenius Kabi USA, LLC

Three Corporate Drive
Lake Zurich, Illinois 60047
T 847-550-2300
T 888-391-6300
www.fresenius-kabi.us

CITIZEN PETITION
VIA ELECTRONIC SUBMISSION 05/24/2019

29 May 2019

Division of Dockets Management
Food and Drug Administration
(HFA-305) Room 1061
5630 Fishers Lane
Rockville, MD 20852

Dear Sir/Madam:

The undersigned submits this petition pursuant to the Federal Food, Drug and Cosmetic Act and 21 CFR 10.30 requesting the Commissioner of the Food and Drug Administration to designate Fresenius Kabi USA, LLC's (FK USA) Fulvestrant Injection approved under 505(b)(2) NDA 210326 as therapeutically equivalent with an 'AB' rating to the reference listed drug (RLD) Faslodex®, NDA 021344, by Astrazeneca Pharmaceuticals LP.

A. Action Requested

The petitioner requests that the Commissioner of the Food and Drug Administration designate Fulvestrant Injection, 50 mg/mL, manufactured by FK USA (NDA 210326), as a therapeutic equivalent, with an 'AB' rating, to the reference listed drug (RLD) Faslodex®, NDA 021344, by Astrazeneca Pharmaceuticals LP.

B. Statement of Grounds

FK USA's Fulvestrant Injection drug product (NDA 210326) is therapeutically and pharmaceutically equivalent to the Reference Listed Drug (RLD), Faslodex®, NDA 021344, by Astrazeneca Pharmaceuticals LP, and is expected to have the same clinical effect and safety profile as the RLD. A side-by-side pharmaceutical comparison of FK USA's NDA 210326 and the RLD NDA 021344 is provided in Table 1 for the reviewer's convenience.

Table 1 Side-by-Side Pharmaceutical Equivalence Comparison of FK USA NDA 210326 and the RLD NDA 021344

Attributes	FK USA NDA 210326	RLD ANDA 021344	Comparison
Strength	250 mg/5 mL	250 mg/5 mL	same
Product presentation	Two prefilled syringes and two needles packaged in a carton	Two prefilled syringes and two needles packaged in a carton	same
Route of Administration	Intramuscular	Intramuscular	same
Dosage Form	Sterile solution	Sterile solution	same
Active Ingredient	Fulvestrant, USP	Fulvestrant, USP	same
Excipients	Benzyl Alcohol, Alcohol 200 Proof, Polysorbate 80, Alpha-Tocopherol, Super refined Castor oil	Benzyl Alcohol, Alcohol 190 Proof, Benzyl Benzoate, Castor Oil	N/A
Labeling Indications	Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.	Faslodex is an estrogen receptor antagonist indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.	same

The "Approved Drug Products with Therapeutic Equivalence Evaluations", ("The Orange Book"), defines pharmaceutically equivalent drug products as follows:

1. Contain identical amounts of the same active drug ingredient in the same dosage form and route of administration
2. Meet compendial or other applicable standards of strength, quality, purity and identity

The "Approved Drug Products with Therapeutic Equivalence Evaluations", ("The Orange Book"), defines therapeutically equivalent drug products as follows:

1. Are approved as safe and effective.
2. Contain identical amounts of the same active drug ingredient in the same dosage form and route of administration
3. Meet compendial or other applicable standards of strength, quality, purity and identity
4. Are bioequivalent
5. Are adequately labeled
6. Were manufactured under cGMP

According to the Orange Book Preface to the 39th Edition, therapeutically equivalent drug products can differ in certain other characteristics, such as shape, scoring configuration, release mechanisms, packaging, excipients, expiration date/time, minor aspects of labeling and storage conditions.

Table 1 demonstrates that the RLD and FK drug products are identical with the exception of the excipients used. These changes in excipients are not expected to alter the pharmacokinetics, safety or efficacy of fulvestrant. However, Fresenius Kabi assessed the systemic exposure to Fulvestrant in its proposed product and the RLD in a clinical bioequivalence bridging study and the results show a comparable rate and extent of absorption for the Fulvestrant Injection and RLD, Faslodex®.

FK USA's Fulvestrant Injection, 505(b)(2) NDA 210326, also relied, in part, on the RLD data and previously published literature for safety and efficacy.

Based on all the above mentioned reasons, FK USA kindly requests the Agency to grant a therapeutic equivalence rating 'AB' for NDA 210326, Fulvestrant Injection.

C. Environmental Impact

In accordance with the requirements set forth in 21 CFR 25.31, FK USA hereby requests a Categorical Exclusion from the requirements to prepare an Environmental Impact Assessment.

D. Economic Impact

Pursuant to 21 CFR 10.30(b) an economic impact analysis will be provided upon request.

E. Certification

FK USA certifies that to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and includes representative data and information known to the petitioner, which are unfavorable to the petition.

Respectfully submitted,

Shruti Patel

Digitally signed by Shruti Patel
DN: c=US, st=Illinois, l=Lake Zurich, o=Fresenius Netcare, ou=IT, cn=Shruti Patel, email=Shruti.Patel@fresenius-kabi.com
Reason: I attest to the accuracy and integrity of this document
Date: 2019.05.29 09:19:52 -05'00'

Shruti Patel
Regulatory Specialist
Phone: 847-550-2342 ‖ Fax: 847-550-7121
E-mail: shruti.patel@fresenius-kabi.com